Background BRCA1 and BRCA2 (BRCA) mutation carriers face a high lifetime risk of developing ovarian cancer. Oral contraceptives are protective in this population; however, the impact of other types of contraception (e.g. intrauterine devices, implants, injections) is unknown. We undertook a matched case-control study to evaluate the relationship between type of contraception and risk of ovarian cancer among women with BRCA mutations. Methods A total of 1733 matched pairs were included in this analysis. Women were matched according to year of birth, date of study entry, country of residence, BRCA mutation type and history of breast cancer. Detailed information on hormonal, reproductive and lifestyle exposures were collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) associated with each contraceptive exposure. Results Ever use of any contraceptive was significantly associated with reduced risk of ovarian cancer (OR = 0.62; 95% CI 0.52–0.75; P < 0.0001), which was driven by significant inverse associations with oral contraceptives (OR = 0.66; 95% CI 0.54–0.79; P < 0.0001) and contraceptive implants (OR = 0.30; 95% CI 0.12–0.73; P = 0.008). We observed a similar effect with use of injections (OR = 0.37; 95% CI 0.10–1.38; P = 0.14), but this did not achieve significance. No significant associations were observed between patterns of intrauterine device use and risk of ovarian cancer. Conclusions These findings support a protective effect of oral contraceptives and implants on risk of ovarian cancer among women with BRCA mutations. The possible protective effect of injections requires further evaluation.

Xia, Y., Gronwald, J., Karlan, B., Lubinski, J., Mccuaig, J., Brooks, J., et al. (2022). Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. GYNECOLOGIC ONCOLOGY, 164(3 (March 2022)), 514-521 [10.1016/j.ygyno.2022.01.014].

Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation

Fruscio R.
Membro del Collaboration Group
;
2022

Abstract

Background BRCA1 and BRCA2 (BRCA) mutation carriers face a high lifetime risk of developing ovarian cancer. Oral contraceptives are protective in this population; however, the impact of other types of contraception (e.g. intrauterine devices, implants, injections) is unknown. We undertook a matched case-control study to evaluate the relationship between type of contraception and risk of ovarian cancer among women with BRCA mutations. Methods A total of 1733 matched pairs were included in this analysis. Women were matched according to year of birth, date of study entry, country of residence, BRCA mutation type and history of breast cancer. Detailed information on hormonal, reproductive and lifestyle exposures were collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI) associated with each contraceptive exposure. Results Ever use of any contraceptive was significantly associated with reduced risk of ovarian cancer (OR = 0.62; 95% CI 0.52–0.75; P < 0.0001), which was driven by significant inverse associations with oral contraceptives (OR = 0.66; 95% CI 0.54–0.79; P < 0.0001) and contraceptive implants (OR = 0.30; 95% CI 0.12–0.73; P = 0.008). We observed a similar effect with use of injections (OR = 0.37; 95% CI 0.10–1.38; P = 0.14), but this did not achieve significance. No significant associations were observed between patterns of intrauterine device use and risk of ovarian cancer. Conclusions These findings support a protective effect of oral contraceptives and implants on risk of ovarian cancer among women with BRCA mutations. The possible protective effect of injections requires further evaluation.
Articolo in rivista - Articolo scientifico
BRCA; Case-control; Contraception; Intrauterine device; Ovarian cancer;
English
514
521
8
Xia, Y., Gronwald, J., Karlan, B., Lubinski, J., Mccuaig, J., Brooks, J., et al. (2022). Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. GYNECOLOGIC ONCOLOGY, 164(3 (March 2022)), 514-521 [10.1016/j.ygyno.2022.01.014].
Xia, Y; Gronwald, J; Karlan, B; Lubinski, J; Mccuaig, J; Brooks, J; Moller, P; Eisen, A; Sun, S; Senter, L; Bordeleau, L; Neuhausen, S; Singer, C; Tung, N; Foulkes, W; Sun, P; Narod, S; Kotsopoulos, J; Yerushalmi, R; Fruscio, R; Rastelli, A; Zovato, S; Hyder, Z; Huzarski, T; Cybulski, C; Sweet, K; Wood, M; Mckinnon, W; Elser, C; Pal, T; Wiesner, G; Friedman, E; Meschino, W; Snyder, C; Metcalfe, K; Poll, A; Gojska, N; Warner, E; Kim, R; Rosen, B; Demsky, R; Ainsworth, P; Panabaker, K; Steele, L; Saal, H; Serfas, K; Panchal, S; Cullinane, A; Reilly, R; Blum, J; Kwong, A; Cybulski, C; Rayson, D; Isaacs, C; Ramón y Cajal, T; Dungan, J; Cohen, S
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/370628
Citazioni
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
Social impact